Patents Examined by John S Kenyon
  • Patent number: 11401254
    Abstract: The present disclosure relates to substituted thiophene carboxamides and analogues thereof of formula (I) that may be used for protecting plants from bacterial diseases, in particular from bacterial diseases caused by bacteria belonging to the genus Xanthomonas.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: August 2, 2022
    Assignee: Bayer Aktiengesellschaft
    Inventors: David Bernier, Stéphane Brunet, Jérémy Dufour, Thomas Knobloch, Lionel Nicolas, Tomoki Tsuchiya
  • Patent number: 11399539
    Abstract: A heterocyclic compound that exhibits superior control effects against harmful arthropods is provided. In particular, a heterocyclic compound of formula (I) is provided, wherein the variable groups are as defined in the specification. Also provided is a composition containing the heterocyclic compound of formula (I) and one or more types of components selected from the components described in the specification.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: August 2, 2022
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Ayaka Tanaka, Masaru Shimomura, Yoshihiko Nokura, Shinichiro Murakami
  • Patent number: 11377465
    Abstract: A pyranoglucose-substituted pyrazole compound, used as a pharmaceutical intermediate, having the structural formula represented by formula (9c). The present invention further relates to an intermediate compound represented by formula (10c) or a salt thereof. The present invention further relates to a preparation method of the aforementioned intermediate compound and a method of using the same to prepare an SGLT inhibitor. By means of the novel key intermediate, the preparation technique of an SGLT inhibitor is greatly simplified. In addition, because the intermediate can be precipitated in the form of a salt and is easy to purify, the purity of the SGLT inhibitor is significantly increased, compared with the original preparation pathway (crude product purity can reach 99% or more).
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: July 5, 2022
    Assignees: Yabao Pharmaceutical Group Co., Ltd., Suzhou Yabao Pharmaceutical R&D Co., Ltd.
    Inventors: Fei Zhang, Peng Wang, Lili Sun, Lin Zhu
  • Patent number: 11365203
    Abstract: Provided are a fluorescent dye and a preparation process and use thereof. The fluorescent dye is able to emit a long wavelength, is sensitive and specific to viscosity, and is used for a wide range of purposes, such as viscosity testing, fluorescent labeling, quantification or detection of proteins, enzymes or nucleic acids. In addition, it can be used as a fluorescent-activated probe.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: June 21, 2022
    Assignee: FLUORESCENCE DIAGNOSIS (SHANGHAI) BIOTECH COMPANY LTD.
    Inventors: Linyong Zhu, Yi Yang, Dasheng Zhang, Zengmin Du, Bingkun Bao, Qiuning Lin, Yan Li, Xianjun Chen, Lipeng Yang, Chunyan Bao
  • Patent number: 11345712
    Abstract: The present disclosure provides compounds, for example, a compound of Formula (I), that modulate a protein function and/or restore protein homeostasis. The disclosure provides a method of modulating a protein-mediated disease, disorder, condition, or response. Compositions, including in combination with other therapeutic agents, are provided.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: May 31, 2022
    Assignee: BioTheryX, Inc.
    Inventors: Kyle W. H. Chan, Paul E. Erdman, Leah Fung, David Aaron Hecht, Imelda Lam, Robert Sullivan, Eduardo Torres
  • Patent number: 11345666
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: May 31, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Virginia M. Tanis, Craig R. Woods
  • Patent number: 11344047
    Abstract: The present disclosure provides methods and formulations for reducing ammonia and carbon dioxide emissions from a bovine using lubabegron, or a physiologically acceptable salt thereof. The present disclosure also provides bovine feed additives and bovine feed compositions.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: May 31, 2022
    Assignee: Elanco US Inc.
    Inventors: Cory T. Herr, John Charles Kube, Jerold Scott Teeter
  • Patent number: 11332462
    Abstract: Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: May 17, 2022
    Assignees: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
    Inventors: John Emmerson Campbell, Una Campbell, Taleen G. Hanania, Liming Shao
  • Patent number: 11325930
    Abstract: The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: May 10, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Eda Y. Canales, Manoj C. Desai, Eric Gorman, Jiayao Li, Roland D. Saito, James G. Taylor, Nathan E. Wright
  • Patent number: 11324720
    Abstract: Methods for inhibiting cell growth, inhibiting DNA polymerase activity, and inhibiting DNA replication and repair are provided. In a method of inhibiting cell growth, a cell, such as a cancer cell, is contacted with zelpolib or a derivative or pharmaceutically acceptable salt thereof. The cell growth can be inhibited in vivo, and in certain embodiments, the cell growth is inhibited in vitro. In a method for inhibiting DNA polymerase activity, a DNA polymerase is contacted with zelpolib or a derivative or pharmaceutically acceptable salt thereof. In certain embodiments, the DNA polymerase is Pol ?. In a method for inhibiting DNA replication and repair, a cell, such as a cancer cell, is contacted with zelpolib or a derivative or pharmaceutically acceptable salt thereof. The DNA replication and repair can be inhibited in vivo, and in certain embodiments, the DNA replication and repair is inhibited in vitro.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: May 10, 2022
    Assignee: NEW YORK MEDICAL COLLEGE
    Inventor: Zhongtao Zhang
  • Patent number: 11324752
    Abstract: Use of imeglimin for the prevention and/or treatment of hepatocellular carcinoma.
    Type: Grant
    Filed: July 4, 2018
    Date of Patent: May 10, 2022
    Assignee: ERICARE
    Inventor: Eric Janin
  • Patent number: 11318122
    Abstract: The present invention describes the combination of a 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine or of a pharmaceutically acceptable salt or solvate thereof with fluoxetine or a pharmaceutically acceptable salt or solvate thereof, for use for treating a synucleinopathy such as Parkinson's disease, Lewy body disease, mutations in the glucocerebrosidase gene, or multiple system atrophy.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: May 3, 2022
    Assignee: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. Chase, Kathleen E. Clarence-Smith
  • Patent number: 11319298
    Abstract: The present invention is directed to heteroarylpiperidine ether compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: May 3, 2022
    Assignees: Merck Sharp & Dohme Corp., MSD R&D (China) Co., Ltd.
    Inventors: Jianming Bao, Ronald Ferguson, Xiaolei Gao, Scott Harrison, Sandra L. Knowles, Michael Man-Chu Lo, Robert D. Mazzola, Jr., Jeffrey W. Shubert
  • Patent number: 11312700
    Abstract: Provided herein are arylcyclopropyl amino-isoquinoline amide compounds. In particular, the disclosure provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the disclosure are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, diseases characterized by abnormal growth, such as cancers, and inflammatory diseases. The disclosure further provides compositions containing isoquinoline amide compounds.
    Type: Grant
    Filed: July 22, 2020
    Date of Patent: April 26, 2022
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Jill M. Sturdivant, Cynthia L. Lichorowic, Andriy Kornilov
  • Patent number: 11312687
    Abstract: A 7H-azulene [1,2,3-i,j] isoquinolin-7-one compound, a single crystal and a use thereof are provided. The compound has a structure as shown in a formula (I). The present invention obtains a crude extract of Acorus calamus L., then extracts with different polar solvents in sequence and separates column chromatography to obtain a novel alkaloid compound, which is expected to be developed into a novel class of drug exerting neuroprotective effects, so as to prevent and treat senile dementia, stroke and epilepsy diseases.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: April 26, 2022
    Assignee: HUNAN UNIVERSITY OF CHINESE MEDICINE
    Inventors: Shunxiang Li, Juan Li
  • Patent number: 11306087
    Abstract: Provided herein are methods of using KRAS G12C inhibitors. These methods of using the inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: April 19, 2022
    Assignee: AMGEN INC.
    Inventors: Brian Alan Lanman, Shon Booker, Clifford Goodman, Anthony B. Reed, Jonathan D. Low, Hui-Ling Wang, Ning Chen, Ana Elena Minatti, Ryan Wurz, Victor J. Cee
  • Patent number: 11304916
    Abstract: Methods for treating Shiga toxicosis, caused by infection with Shiga toxin bacteria, are provided. The methods include administering to a subject in need thereof an effective amount of one or more active agents selected from tamoxifen, 4-hydroxytamoxifen, endoxifen, toremifene, raloxifene, bazedoxifene, and pharmaceutically acceptable salts thereof. In some embodiments, the methods further include the administration of an antibiotic or a manganese compound to the subject. Pharmaceutical compositions for the treatment of Shiga toxicosis are also described.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: April 19, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Somshuvra Mukhopadhyay, Andrey S. Selyunin, Stanton F. McHardy
  • Patent number: 11306082
    Abstract: The present invention relates to a compound of formula (I) including any stereochemically isomeric form thereof, or a pharmaceutically acceptable salt thereof. wherein R1 is —C(?O)O-alkyl, carbonate ester, or —C(?O)-alkyl, ester, or —C(?O)N-alkyl, carbamate ester and wherein R2 is —CH3 or —CD3. The alkyl ester can contain saturated or unsaturated C12 to C26 alkyl carbon. The alkyl carbon chain can have either a straight, branched, noncyclic, cyclic, unsubstituted or substituted structure.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: April 19, 2022
    Assignee: Foresee Pharmaceuticals Co., Ltd.
    Inventors: Yuhua Li, Chen-Chang Lee, Wen-Yen Huang
  • Patent number: 11299507
    Abstract: The present invention relates to the technical field of chiral synthesis, and specifically provides a new type of oxa-spirodiphosphine ligands. The bisphosphine ligand is prepared with oxa-spirobisphenol as a starting material after triflation, palladium catalyzed coupling with diaryl phosphine oxide, reduction of trichlorosilane, further palladium catalyzed coupling with diaryl phosphine oxide, and further reduction of trichlorosilane. The oxa-spiro compound has central chirality, and thus includes L-oxa-spirodiphosphine ligand and R-oxa-spirodiphosphine ligand. The racemic spirodiphosphine ligand is capable of being synthesized from racemic oxa-spirobisphenol as a raw material. The present invention can be used as a chiral ligand in the asymmetric hydrogenation of unsaturated carboxylic acids. The complex of the ligand with ruthenium can achieve an enantioselectivity of greater than 99% in the asymmetric hydrogenation of methyl-cinnamic acid.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: April 12, 2022
    Assignee: SHENZHEN CATALYS TECHNOLOGY CO., LTD.
    Inventors: Xumu Zhang, Genqiang Chen, Jiaming Huang
  • Patent number: 11286226
    Abstract: Disclosed are new polycyclic carbogenic molecules and their methods of synthesis. The new polycyclic carbogenic molecules may be utilized in anti-cancer therapies. In particular, the polycyclic carbogenic molecules may be formulated as pharmaceutical compositions that comprise the small molecules, which compositions may be administered in methods of treating and/or preventing cell proliferative diseases and disorders such as cancer. The new polycyclic carbogenic molecules may be prepared from vinyl- or allyl-substituted cyclohexenone precursors via preparation of a silyl bis-enol ether intermediate.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: March 29, 2022
    Assignee: Northwestern University
    Inventors: Regan James Thomson, Emily E. Robinson